Epididymoorchitis Due toBrucella mellitensis:A Retrospective Study of 59 Patients
Author(s) -
Amalia NavarroMartínez,
Javier Solera,
J. M. Corredoira,
José Luís Beato,
Elisa MartínezAlfaro,
M Atiénzar,
Javier Ariza
Publication year - 2001
Publication title -
clinical infectious diseases
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/324489
Subject(s) - medicine , brucellosis , doxycycline , brucella melitensis , orchitis , brucella , surgery , sulfamethoxazole , trimethoprim , antibiotics , aminoglycoside , retrospective cohort study , gastroenterology , immunology , microbiology and biotechnology , biology
Epididymoorchitis is a focal form of human brucellosis described in 2%-20% of patients with brucellosis. We assessed 59 cases of Brucella epididymoorchitis (BEO) between 1991 and 1999. The median age of patients was 34 years (range, 15-75 years). The onset of symptoms was acute in 46 patients (78%). Scrotal pain and swelling (100% of patients), fever (88%), and sweating (73%) were the most common symptoms. Brucella species was isolated from blood cultures in 41 patients (69%) and from epididymal aspiration in 4 patients. Treatment consisted of a combination of a doxycycline and an aminoglycoside (n=39) or rifampin (n=10); trimethoprim-sulfamethoxazole with rifampin (n=3); or trimethoprim-sulfamethoxazole as monotherapy (n=7). The median duration of therapy was 45 days (range, 21-90 days). The infections of 9 patients (15%) failed to respond to therapy, and 15 patients relapsed (25%). Three patients with necrotizing orchitis whose infections were unresponsive to antibiotics required an orchiectomy. In general, classical brucellosis therapy is adequate for BEO.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom